SANOFI-ADR
SNYNASDAQTrading Snapshot
- Day Range
- $39.87 β $40.67
- 52-Week Range
- $40.66 β $52.68
- Volume
- $3.84B
- Avg Volume
- $2.60B
- Shares Outstanding
- 2.40B
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $46.72B
- Last Q Revenue
- $12.30B
- P/E Ratio
- 22.0
- P/S Ratio
- 1.8x
- EPS (TTM)
- $1.65
- Dividend Yield
- 11.61%
- Dilution (1yr)
- β2.6%
Why Investors Own SNY
- βHigh-growth profile β revenue up -0.7% YoY with expanding US Equity exposure.
- βHealthy economics β 28% gross margin and 14% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SANOFI-ADR
SNYAbout SANOFI-ADR
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
SANOFI-ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift SNY price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
SANOFI-ADR announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.